See also this year's filing and all EDGAR filings for this company.
PDF Report 0001503802_2023_Karyopharm_Therapeutics_Inc.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Expenses', 'missing_ratio': 0.017705276600369524, 'aggregate_val': 299645000, 'exp_sum': 294432000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 145401000, 'ResearchAndDevelopmentExpense': 148662000, 'remainder_Expenses': 369000}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001503802, Karyopharm Therapeutics Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 350,162,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 1,139,000 |
| 3 | remainder_Assets | 6,871,000 |
| 4 | LiabilitiesCurrent | 65,908,000 |
| 5 | LiabilitiesNoncurrent | 6,097,000 |
| 6 | remainder_Liabilities | 302,823,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 145,401,000 |
| 9 | ResearchAndDevelopmentExpense | 148,662,000 |
| 10 | remainder_Expenses | 5,582,000 |
| 11 | remainder_Revenues | 157,074,000 |
| 12 | remainder_NetIncome | -22,720,000 |
| 13 | remainder_ComprehensiveNetIncome | -829,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 358,172,000 |
| 1 | Liabilities | 374,828,000 |
| 2 | Expenses | 299,645,000 |
| 3 | Revenues | 157,074,000 |
| 4 | StockholdersEquity | -16,656,000 |
| 5 | NetIncome | -165,291,000 |
| 6 | ComprehensiveNetIncome | -165,705,500 |
| 7 | BaseVar | 606,634,000 |
| 8 | EconomicCapitalRatio | -0.530 |
Edgar->Model Mapping
Feature Distribution
Change over Time
